MALCOLM BRENNER to Neomycin
This is a "connection" page, showing publications MALCOLM BRENNER has written about Neomycin.
Connection Strength
0.180
-
Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease. Hum Gene Ther. 2000 Jul 01; 11(10):1465-75.
Score: 0.045
-
Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease. Hum Gene Ther. 1998 May 20; 9(8):1237-50.
Score: 0.038
-
Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood. 1994 Jul 15; 84(2):380-3.
Score: 0.029
-
Gene marking to improve the outcome of autologous bone marrow transplantation. Prog Clin Biol Res. 1994; 389:587-91.
Score: 0.028
-
Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet. 1993 Jan 09; 341(8837):85-6.
Score: 0.027
-
Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. Hum Gene Ther. 1994 Mar; 5(3):381-97.
Score: 0.007
-
Molecular analysis of retroviral transduction in chronic myelogenous leukemia. Hum Gene Ther. 1991; 2(4):317-21.
Score: 0.006